Tag Archives: CDKs

April, 2016

• 20 April

  Pfizer Announces Positive Top-Line Results from its Late-Stage Breast Cancer Trial

  

  Tuesday, April 19, 2016 – 8:00am EDT Pfizer Inc. (NYSE:PFE) today announced positive top-line results from the Phase 3 PALOMA-2 trial for IBRANCE®(palbociclib), an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6.1 The study met its primary endpoint by demonstrating an improvement in progression-free survival (PFS) for the combination …

  Share

  • Facebook
  • Twitter
  • LinkedIn

March, 2016

• 9 March

  Researchers Discover New Therapeutic Targets for Myeloma

  

  Despite new therapies, Multiple Myeloma (MM) remains incurable causing most patients to ultimately develop drug resistance and succumb to the disease. The pursuit of drugs that inhibit cell cycle regulators especially cyclin-dependent kinases (CDKs), has been an intense focus of research in cancer. A new study by researchers at The …

  Share

  • Facebook
  • Twitter
  • LinkedIn